By admin 
The rhythmic thud of my sneakers on the treadmill belt was the only sound competing with Prince’s "Raspberry Beret" as I pushed toward a physical brink I rarely visit. Clad in a restrictive rubber mask that felt like a prop from a dystopian film—specifically the one worn by the villain Bane—I was undergoing a VO2 Max test at a sleek, high-tech clinic in Chicago. Every minute, the incline increased, and every minute, the woman monitoring my vitals asked me to rank my perceived exertion. I was at an eight, then a nine, and finally a gasping ten. This grueling assessment, which measures the maximum amount of oxygen a person can utilize during intense exercise, is widely considered the single most accurate predictor of cardiorespiratory fitness and, by extension, long-term mortality. It was also the centerpiece of a $5,500 comprehensive longevity evaluation I underwent at a facility affiliated with Northwestern University, marking the beginning of an investigation into how the pursuit of eternal youth has moved from the fringes of "biohacking" into the hallowed halls of American academia.
This experience represents Part 1 of "Selling Longevity," a deep dive into an industry that is currently undergoing a radical transformation. For decades, the quest to halt or reverse the aging process was the domain of eccentrics and outliers. We have moved from the 1920s, when surgeons like Serge Voronoff claimed to rejuvenate men by grafting thin slices of monkey testicles onto their own, to the modern-day extremes of tech mogul Bryan Johnson, who famously spent millions on a regimen that included blood plasma transfusions from his teenage son—a practice he eventually abandoned after finding no clinical benefit. However, the narrative is shifting. Today, the most prestigious names in American healthcare, including Northwestern Medicine, the Mayo Clinic, and Mount Sinai, are entering the fray. They are offering "longevity packages" that promise to replace pseudoscience with rigorous, data-driven protocols designed to extend not just the number of years a person lives, but the number of years they live in peak health—a concept known as "healthspan."
The emergence of these hospital-backed clinics marks a pivotal moment in the "Longevity Economy," a market projected by some analysts to reach a valuation of over $600 billion by the end of the decade. These programs are designed for the "worried well"—individuals who are not currently sick but are willing to pay a premium to ensure they stay that way. The standard of care in traditional American medicine is largely reactive; doctors typically treat diseases after they manifest. Longevity medicine seeks to flip this script, using a battery of advanced diagnostics to identify the earliest whispers of decline in the heart, lungs, brain, and metabolic systems.
At the Northwestern-affiliated clinic, the $5,500 entry fee buys a level of scrutiny that far exceeds the typical annual physical. Beyond the VO2 Max test, patients undergo dual-energy X-ray absorptiometry (DEXA) scans to measure bone density and precise body fat distribution—visceral fat, the kind that wraps around organs, is a key marker for chronic inflammation. They may receive "liquid biopsies" that screen for cancer DNA in the bloodstream, or epigenetic "clocks" that claim to measure biological age by looking at chemical tags on the genome. There are cognitive assessments to detect early signs of neurodegeneration and exhaustive blood panels that look for everything from ApoB (a critical marker for cardiovascular risk) to IGF-1 levels.
However, this transition from "fringe" to "institutional" has not occurred without significant friction. Critics and bioethicists are increasingly vocal about the tensions inherent in these programs. One of the primary concerns is the disconnect between the clinics’ high out-of-pocket costs and the nonprofit status of the parent hospitals. Most of these longevity assessments are not covered by insurance, creating a two-tiered system where the wealthy can purchase a "biological edge" while the average patient struggles to access basic preventative care. Furthermore, there is the question of scientific validity. While a VO2 Max test is grounded in decades of exercise physiology, other offerings—such as certain "biological age" tests or extensive whole-body MRIs for asymptomatic individuals—lack robust, large-scale clinical evidence proving they actually lead to better health outcomes or longer lives.
The debate often centers on the "over-diagnosis" trap. In the medical community, there is a well-documented risk that excessive testing in healthy people will lead to "incidentalomas"—benign abnormalities that show up on scans, leading to unnecessary anxiety, invasive follow-up biopsies, and expensive treatments for conditions that may never have caused a problem. "We are in an era where technology has outpaced our understanding of the data it produces," says one skeptical geriatrician. "Just because we can measure a biomarker doesn’t mean we know how to change it, or that changing it will make you live longer."
Despite these warnings, the demand is insatiable. The modern consumer is increasingly disillusioned with a healthcare system that feels like a "sick-care" system. This has paved the way for the rise of the "Longevity Physician," a new breed of doctor who combines traditional medicine with elements of coaching, nutrition, and performance optimization. These practitioners argue that waiting for a patient to meet the clinical criteria for Type 2 diabetes or heart disease is a failure of the system. Instead, they aim for "optimal" levels rather than "normal" levels. If a patient’s blood sugar is in the high end of the "normal" range, a longevity clinic might prescribe lifestyle interventions or even off-label medications like Metformin or Rapamycin—drugs that have shown life-extending potential in animal studies but have yet to be proven as anti-aging panaceas in healthy humans.
The historical context of this movement adds a layer of irony to the current boom. The desire to cheat death is as old as humanity, but the methods have evolved from the mystical to the molecular. In the mid-20th century, the focus was on vitamins and hormones; in the early 2000s, it was the promise of stem cells and telomere lengthening. Each wave of enthusiasm eventually hit a wall of clinical reality. The current wave, however, feels different because it is being led by institutions that have historically been the gatekeepers of medical truth. When a top-tier university hospital puts its brand on a longevity center, it provides a "halo effect" that can obscure the fact that much of the field remains experimental.
Logical analysis of the industry’s growth suggests that the financial incentives are perfectly aligned for hospitals to expand these services. As reimbursement rates from Medicare and private insurers for traditional procedures continue to tighten, "cash-pay" wellness services offer a lucrative revenue stream with high margins. This creates a moral hazard: Are hospitals promoting these tests because they are essential for health, or because they are essential for the bottom line?
Expert perspectives on the matter are sharply divided. Proponents, such as Dr. Peter Attia, author of the bestselling longevity manifesto Outlive, argue that the current medical establishment is stuck in "Medicine 2.0," which is excellent at treating acute trauma and infectious disease but terrible at managing the "Four Horsemen" of slow death: heart disease, cancer, neurodegenerative disease, and type 2 diabetes. Attia and his peers advocate for "Medicine 3.0," a proactive approach that uses every tool available—even those where the evidence is still emerging—to delay the onset of these chronic conditions.
On the other side of the aisle, public health experts point out that the most effective "longevity interventions" are already well-known and surprisingly cheap: regular exercise, a balanced diet, adequate sleep, and social connection. They worry that the "medicalization" of aging through expensive clinics distracts from the systemic issues that actually determine lifespan, such as socioeconomic status, environmental pollution, and access to healthy food.
As I finished my VO2 Max test in Chicago, dripping with sweat and gasping for air, the data on the screen provided a snapshot of my physiological ceiling. It told me where I stood compared to other women my age and what my "fitness age" was. It was empowering information, but it also felt like the beginning of a never-ending cycle of monitoring and optimization. The "Selling Longevity" series will continue to explore this cycle, investigating the supplements being sold in clinic lobbies, the data privacy concerns of sharing genetic information with private corporations, and the philosophical question of what happens to a society when aging is treated not as a natural process, but as a disease to be cured. For now, the clinics remain full, the treadmills remain at a steep incline, and the promise of a longer, more vibrant life remains the most compelling product on the market—provided you have the thousands of dollars required to buy into the dream.
